MedTrace Logo

Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease

NCT00456859 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2007-10-18

No results posted yet for this study

Summary

The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel group comparison clinical trial and will be conducted as a researcher-directed study to assess the efficacy of Kremezin in preventing the progression of CKD. We compare two groups of patients: those receiving conventional treatment alone and those receiving such treatment paired with Kremezin.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Kremezin

Sponsors & Collaborators

  • Institute for Health Outcomes and Process Evaluation Reseach

    lead OTHER

Principal Investigators

  • Yasushi Asano · Jichi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2007-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456859 on ClinicalTrials.gov